Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 2107

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 10
Chunk 2107
---
 unamortized stock compensation to be recognized is 1.75 years.

Warrants

The
following is an analysis of the stock warrant grant activity:

 Schedule
of analysis of the stock warrant grant

    Weighted Average  
    Weighted Average 

    Number of Shares  
    Exercise Price  
    Remaining Life 

    Stock Warrants 

    Outstanding December 31, 2023 
     —  
    $—  
     — 

    Granted 
     55,000  
    $7.50  
     4.99 

    Expired 
     —  
    $—  
     — 

    Exercised 
     —  
    $—  
     — 

    Outstanding December 31, 2024 
     55,000  
    $7.50  
     4.13 

    Exercisable December 31, 2024 
     55,000  
    $7.50  
     4.38 

    F-24 

A
summary of the status of the Company’s nonvested warrants as of December 31, 2024, and changes during the year ended December
31, 2024, is presented below:

 Schedule
of  nonvested warrants

    Non-vested
    Warrants
     
    Warrants

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31,
    2023

    —

    $
    —

    Granted

    55,000

    $
    7.50

    Vested

    (55,000
    )
     
    $
    7.50

    Forfeited

    —

    $
    —

    Non-vested at
    December 31, 2024

    —

    $
    —

The
total number of warrants granted during the years ended December 31, 2024 and 2023 was 55,000 and 0, respectively.
The exercise price for these warrants was $7.50 per share and there was an intrinsic value of $0.

The
Company recognized stock-based compensation expense related to warrant vesting amortization of $0 and $0 for the years ended December
31, 2024 and 2023, respectively.

On
February 21